Related Experiment Videos
Anticoagulation therapy in children with mechanical prosthetic cardiac valves
Insights
Warfarin use in children with mechanical cardiac valves increases hemorrhage risk but is superior to antiplatelet drugs for preventing life-threatening thromboembolism. Warfarin is indicated for anticoagulation in this pediatric population.
Area of Science:
- Cardiology
- Pediatric Medicine
- Pharmacology
Background:
- Mechanical cardiac prostheses in pediatric patients require long-term anticoagulation to prevent thromboembolic events.
- Choosing the optimal anticoagulation strategy in children is challenging due to risks of bleeding and thrombosis.
Purpose of the Study:
- To compare the efficacy and safety of warfarin versus acetylsalicylic acid and dipyridamole for thromboembolism prophylaxis in children with mechanical cardiac valve replacements.
Main Methods:
- A retrospective study of 28 children (mean age 7.9 years) who underwent cardiac valve replacement between 1980 and 1984.
- Patients received either warfarin or acetylsalicylic acid and dipyridamole for thromboembolism prophylaxis.
- Incidence and frequency of thromboembolism and hemorrhage were compared between the two groups.
Main Results:
- Warfarin-treated patients had a significantly higher risk of hemorrhage (25% vs 0%, p<0.05), though episodes were mild.
- Patients not receiving warfarin had a significantly greater risk of thromboembolism (20% vs 0%, p<0.05), with both episodes being life-threatening.
- Thromboembolic events necessitated emergency valve replacement.
Conclusions:
- Warfarin is associated with an increased risk of hemorrhage compared to acetylsalicylic acid and dipyridamole in pediatric patients with mechanical cardiac valves.
- Despite the higher bleeding risk, warfarin demonstrates superior efficacy in preventing life-threatening thromboembolic events.
- Warfarin is indicated for anticoagulation therapy in children with mechanical cardiac prostheses due to its effectiveness in thromboembolism prophylaxis.
Abstract:
From 1980 through 1984, 28 children younger than 19 years (mean 7.9) underwent cardiac valve replacement with 30 mechanical prostheses. Patients were followed for a total of 471 months (mean 15.7) and received either warfarin (mean 0.16 mg/kg/day) or acetylsalicylic acid and dipyridamole (mean 6.1 and 1.9 mg/kg/day, respectively) as thromboembolism prophylaxis. The frequency and incidence of thromboembolism and hemorrhage were compared. Warfarin-treated patients were at increased risk of hemorrhage (5 of 20 [25%], or 22 per 100 patient-years, vs 0 of 10 [0%], or 0 per 100 patient-years, p less than 0.05). Three of the 5 hemorrhagic episodes were mild, and in no case was hemorrhage life-threatening. Patients who did not receive warfarin had a greater risk of thromboembolism (2 of 10 [20%], or 12 per 100 patient-years, vs 0 of 20 [0%], or 0 per 100 patient-years, p less than 0.05). Both episodes of thromboembolism were life-threatening and necessitated emergency valve replacement. Although warfarin is associated with greater risk of hemorrhage than is acetylsalicylic acid and dipyridamole, warfarin is better than antiplatelet drugs in thromboembolism prophylaxis and is indicated for anticoagulation therapy in children with mechanical cardiac prostheses.